Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study published in the Journal of the National Cancer Institute found that urinary tract cancer is associated with the use of Chinese herbal products containing aristolochic acid. The risk increased with higher doses and was independent of arsenic exposure. The authors recommend continued surveillance and monitoring of patients who h...
Researchers found that restricting glucose intake extends normal human cell lifespan and impairs precancerous cell growth through epigenetic control. The study, published in the FASEB Journal, could lead to novel approaches to extend human lifespan and prevent cancer.
Key advances in DNA sequencing technology and gene mutations have identified candidate cancer genes that contribute to colorectal cancer. The study also highlights the importance of understanding biological pathways deregulated in colon cancer, which can form the basis of new therapeutic agents.
A group of heart drugs, cardiac glycosides, have been found to be effective against human colon cancer cells, with varying degrees of sensitivity. The findings suggest that these heart drugs could potentially improve colon cancer outcomes when used alone or in combination with conventional chemotherapy.
Researchers at Purdue University have developed nanoprobes that deliver cancer drugs directly to tumor cells, reducing damage to healthy cells. The nanoprobes mimic the natural delivery system of endosomes and can track their distribution within cells.
Postmenopausal women taking antidepressants may be at higher risk of stroke and death compared to those not taking the medication. Researchers emphasize the need for individualized risk assessment and further study to determine the exact association.
Researchers at Tel Aviv University have discovered a new mechanism for DNA packaging that affects RNA splicing, leading to differences in protein production. This finding has significant implications for disease diagnosis and treatment, including the development of innovative drug therapies.
A Johns Hopkins-led study finds that while the US has more accessible high-priced cancer drugs, many patients in both countries face financial obstacles due to high out-of-pocket costs. The UK system is considered fairer, but both nations struggle with rationing and end-of-life care decisions.
A new hybrid agent, T-DM1, has shown promising results in a Phase 2 clinical trial for metastatic HER2-positive breast cancer. The compound shrunk tumors by 30% or more in 40% of women with confirmed HER2-positive cancers, and had a total clinical benefit rate of approximately 53%.
A new study presents a promising approach to re-sensitize breast cancer to standard therapy after it becomes resistant. The treatment combination of an aromatase inhibitor and sorafenib shows encouraging responses in 20% of post-menopausal women with metastatic breast cancer, offering a potential new treatment option.
Researchers have discovered a molecular mechanism that can be arrested in human cancer cells, causing them to die without affecting normal body cells. The compound, initially developed for stroke prevention, was found to be effective against breast cancer cells with no toxicity to normal cells.
A new cancer drug, R-Roscovitine, has been found to kill eosinophils that exacerbate asthma symptoms. Researchers believe this could offer an alternative treatment for resistant asthma patients.
Researchers at the University of Florida have found a way to use reduced dosages of the chemotherapy drug TMZ to achieve better results against colon cancer cells. By combining TMZ with a small molecule, they were able to disable the ability of tumor cells to repair DNA damage.
A phase III trial showed that defibrotide was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease. The mortality rate 100 days after transplant was reduced to 62 percent for patients receiving defibrotide.
Researchers identified a critical pathway that stimulates Mdm2 production, binding to and extinguishing tumor suppressors like p53. Preventing Mdm2's destruction is crucial to preventing cancer from spreading within the body.
Dr. Matthew Levy has received $700,000 in Stand Up To Cancer funding to develop self-guiding drugs that target only cancer cells, reducing serious side effects of current therapies.
Researchers at Dana-Farber Cancer Institute found that midostaurin, a kinase inhibitor targeting FLT3 cell receptor, combined with chemotherapy reduced circulating leukemia cells in AML patients. Complete responses occurred in 80% of patients with mutated FLT3, and high survival rates were observed one and two years after treatment.
A phase II clinical trial shows that carfilzomib induces a response in 45% of patients with relapsed or resistant multiple myeloma, reducing neuropathy side effects. The drug also demonstrates good tolerability and dose flexibility.
A randomised trial found that medroxyprogesterone acetate is significantly more effective than venlafaxine at reducing hot flushes in men treated with androgen suppression therapy. Cyproterone acetate was also effective, but medroxyprogesterone is recommended as the standard treatment due to its fewer side effects.
Early clinical trial results show bortezomib-based therapy improves control of graft-versus-host disease and immune system recovery. The treatment was safe with little toxicity, and immune cell reconstitution was significantly improved in the early post-transplant period.
Researchers found that omacetaxine achieved durable responses in CML patients with the T315I mutation, who have limited treatment options. The injectable drug works by a different mechanism than current therapies and has shown promise for expanded use.
A non-absorbed oral co-polymer therapy under development by Midway Pharmaceuticals demonstrates ability to protect against radiation damage and prevent lethal bacterial infections in animal models. The compound, PEG 15-20, may provide new way to prevent serious GI side effects of radiation in cancer patients.
A U-M study found that only 6% of high-risk women were likely to take tamoxifen, a drug proven to prevent breast cancer, due to concerns over side effects. The decision aid provided tailored information about the drug's risks and benefits, improving understanding but not changing behavior.
Researchers found a way to turn ineffective cancer drugs into effective fighters using their patented chemical compound, SHetA2. The compound tricks cancer cells into responding to new treatments and undergoing cell suicide without harming normal cells.
Researchers found that Erbitux, a cancer treatment drug, reversed symptoms of Ménétrier's disease in nearly half of patients. The study provides new hope for those suffering from this rare condition.
Researchers have identified a number of proteins that allow them to distinguish between cancer and normal cells with high accuracy. This discovery may lead to the development of drugs specifically targeting these proteins to inhibit their activation.
A new Indiana University School of Medicine study found that involving family members in medical rounds improves care and communication. Families reported increased feelings of inclusion, respect, and a better understanding of their child's care. Participation is voluntary, and family members can ask questions and offer input.
A new compound, PU-H71, has been discovered that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma. The compound was found to suppress tumor formation in lab testing and animal models.
Researchers at Agios Pharmaceuticals have discovered that the mutated IDH1 gene produces a metabolite called 2-hydroxyglutarate, which contributes to the formation and progression of gliomas. This finding validates cancer metabolism as an approach to identify new ways to treat cancer.
The editorial highlights exaggerated fears and hopes in media coverage of cancer research, such as uncontrolled study results and unwarranted fear from studies. Journalists can alleviate this problem by asking the right questions, highlighting study limitations, and providing data to support claims.
New studies show that morphine can boost tumor-cell proliferation and inhibit the immune response, promoting angiogenesis and cancer metastasis. Shielding lung cancer cells from opiates reduces cell proliferation, invasion, and migration in both cell-culture and mouse models.
Researchers have developed a new mouse variety that approximates human genetic diversity, allowing for more accurate testing of chemotherapeutic drugs. The study aims to reduce the risk of adverse reactions and improve treatment outcomes for cancer patients.
The Tulane Cancer Center is conducting a phase III randomized clinical trial for Alpharadin, an injectable treatment targeting radioactive substance Radium-223. Early trials suggest it may prolong survival for men with bone metastases from prostate cancer.
Researchers successfully delivered high-dose chemotherapy to malignant brain tumors via intra-arterial Avastin, potentially avoiding common side effects of systemic chemotherapy. The innovative technique has shown promising results in early trials and may offer a new treatment option for patients with resistant brain tumors.
Researchers at Karolinska Institutet have identified a paradoxical protein that stimulates stem cell division but prevents cancer growth. The study suggests a potential new treatment using the drug imatinib to prevent colon cancer in high-risk patients.
Researchers at Cornell University College of Veterinary Medicine have discovered that inactivating the Hus1 gene efficiently kills cells lacking p53, a gene mutated in most human cancers. The study provides an important new understanding of cancer cells and their weaknesses.
Researchers discovered that Stapled Peptides can potently and directly inhibit the Notch transcription factor complex, preventing cancer cell proliferation and survival. The findings validate the potential of Stapled Peptides to modulate key intracellular biological targets.
Researchers have devised a new way to disarm the key protein NOTCH, which drives tumor growth. The discovery lays the foundation for a new therapy aimed at critically important transcription factors that could treat various diseases, including multiple types of cancer.
A new study published in Cancer Research found that a potential drug for lung cancer eliminated tumours in 50% of mice and stopped growth and resistance to treatment. The researchers are planning to take the drug into clinical trials to establish its effectiveness for patients with small cell lung cancer.
A new study linked erythropoiesis-stimulating agents (ESAs) to a higher risk of venous thromboembolism in cancer patients. The analysis, published in the Journal of the National Cancer Institute, suggests that ESAs may not be worth the increased risk of blood clots.
A study published in the Journal of the National Cancer Institute found that erythropoiesis-stimulating agents increase the risk of venous thromboembolism in cancer patients. The use of these agents, approved to reduce blood transfusions during chemotherapy, may outweigh benefits due to associated risks.
Researchers at University of Wisconsin-Madison used two FDA-approved drugs to eliminate and prevent cervical cancer in mice. The drugs, which block estrogen's ability to bind to cells, cleared precancerous growths and prevented cancer onset in mice with HPV-positive lesions.
Researchers found that Bortezomib shuts down cellular machines that destroy Runx2, a protein complex that blocks the growth of bone cancer cells. The study suggests that Bortezomib may represent a new treatment option for osteosarcoma, a devastating disease that responds poorly to current chemotherapies.
Researchers at Johns Hopkins University discovered a 1930s gonorrhea medication, acriflavine, that can halt the growth of new blood vessels in cancer cells. By inhibiting HIF-1, a protein essential for tumor growth, acriflavine may one day be incorporated into chemotherapy cocktails to fight cancer.
Researchers at OHSU Knight Cancer Institute have found a combination of radiation therapy and chemotherapy given before prostate removal to be safe and potentially reduce cancer recurrence rates. The treatment regimen resulted in improved outcomes, with clean cancer margins and undetectable PSA levels in patients.
A review of nearly 150 papers found that tinnitus causes significant distress, with many patients told nothing can be done to alleviate symptoms. The researchers advocate for increased support, guidance, and treatment options for those affected.
Researchers have developed tumor-penetrating microparticles (TPM) to deliver drugs more effectively, targeting both rapid- and slow-growing tumors. TPM has shown promise in treating pancreatic cancer by breaking through barriers and delivering highly concentrated drug doses.
Research into breast cancer development, chronic pain and inflammatory diseases receives ARC funding to investigate epigenetic modifiers, immune responses and protein interactions. The institute aims to develop basic discoveries into clinical benefits for patients worldwide.
Researchers at Duke University have developed a simple and inexpensive method for loading cancer drugs into nano-scale delivery vehicles. The new formulation showed promising results in animal models, eliminating tumors after a single treatment while reducing side effects associated with systematic chemotherapy.
A new study found that switching to a newer type of immunosuppressant drug, sirolimus, reduced the rate of skin cancer in kidney transplant patients by 25%. Nearly half of patients stopped treatment due to side effects. The researchers believe this could offer a new option for reducing skin cancer risk in transplant recipients.
A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients taking anti-tumor necrosis factor (TNF) therapy did not experience an elevated cancer risk. The study included data from 6,366 patients and compared their cancer risk to those who were not taking TNF inhibitors or using other immunosuppressant drugs.
UT Southwestern researchers successfully used a combination of the investigational drug BEZ235 and low-dose radiation to eliminate non-small cell lung cancer in mice. The treatment targeted the PI3K protein pathway, which is often activated in K-RAS mutated tumors, making these cancers resistant to traditional treatments.
The university's partnership with UCLA will enhance its capability to conduct high-quality cancer research, recruit more investigators, and strengthen outreach programs. The grant will also enable the university to add students and clinical fellows as future cancer researchers.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
A consortium led by UT Health Science Center at Houston is establishing a center to conduct innovative cancer research, focusing on transport oncophysics and targeting liver cancers. Researchers aim to develop new approaches to studying cancer processes and exploiting its weaknesses to mount decisive attacks against metastatic disease.
Researchers found that statins can inhibit growth and development of cancer cells, as well as treat diabetes and neurological disorders like Parkinson's. The study used the nematode C. elegans as an ideal test subject, showing dramatic effects on enzyme activity.
Researchers identified a cellular pathway by which alcohol promotes cancer progression through the activation of EMT in colon and breast cancer cells. This mechanism may contribute to the increased risk of these cancers associated with alcohol consumption.
A Dartmouth study has found that patients taking immunosuppressive drugs such as glucocorticoids may be at higher risk of developing bladder cancer. The research examined the long-term use of glucocorticoids in 786 bladder-cancer patients and 1,083 control subjects, revealing a potential link between the two.
A study found that patients with IBD, particularly those on thiopurine medications, may be at higher risk for non-melanoma skin cancer. The study also showed that recent use of immunosuppressive medications was associated with increased risk of NMSC.
A new Johns Hopkins Engineering in Oncology Center will study physical underpinnings of cancer growth and spread, aiming to develop innovative therapies and diagnostic tools. Researchers hope to gain a better understanding of the complex forces involved in metastasis.